Alemtuzumab vs. Rebif in RRMS
The OSU Multiple Sclerosis Center is doing a research study for MS patients with one or more relapses within the last 12 months. This is A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Relapsing-Remitting Multiple Sclerosis.
For more information or to enroll in this study, please contact Lisa Hafer in the Department of Neurology at 614-293-7877, or e-mail Lisa.Hafer@osumc.edu